What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study
Authors:
- Michael JewettMJMichael Jewett
- Grant D StewartGSGrant D Stewart
- International Neoadjuvant Kidney Cancer Consortium (INKCC) membersIMInternational Neoadjuvant Kidney Cancer Consortium (INKCC) members
- 4 June 2025
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (10) , 1231-1234
Abstract
No abstract availableFunding Information
- International Kidney Cancer Consortium
This publication has 5 references indexed in Scilit:
- Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi StudyEuropean Urology Oncology, 2025
- A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesEuropean Urology, 2025
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell CarcinomaNew England Journal of Medicine, 2024
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumThe Lancet Oncology, 2019
- Research guidelines for the Delphi survey techniqueJournal of Advanced Nursing, 2000